Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 38

1.

Vaccine therapy for prostate cancer.

Sonpavde G, Spencer DM, Slawin KM.

Urol Oncol. 2007 Nov-Dec;25(6):451-9. Review.

PMID:
18047951
2.

B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome.

Zang X, Thompson RH, Al-Ahmadie HA, Serio AM, Reuter VE, Eastham JA, Scardino PT, Sharma P, Allison JP.

Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19458-63. Epub 2007 Nov 27.

3.

B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy.

Roth TJ, Sheinin Y, Lohse CM, Kuntz SM, Frigola X, Inman BA, Krambeck AE, McKenney ME, Karnes RJ, Blute ML, Cheville JC, Sebo TJ, Kwon ED.

Cancer Res. 2007 Aug 15;67(16):7893-900. Epub 2007 Aug 8.

4.

Immunotherapy with dendritic cells for prostate cancer.

Thomas-Kaskel AK, Waller CF, Schultze-Seemann W, Veelken H.

Int J Cancer. 2007 Aug 1;121(3):467-73. Review.

5.

Prostate cancer.

Penson DF, Chan JM; Urologic Diseases in America Project.

J Urol. 2007 Jun;177(6):2020-9.

PMID:
17509282
6.

The new B7s: playing a pivotal role in tumor immunity.

Flies DB, Chen L.

J Immunother. 2007 Apr;30(3):251-60. Review.

PMID:
17414316
7.

PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.

Inman BA, Sebo TJ, Frigola X, Dong H, Bergstralh EJ, Frank I, Fradet Y, Lacombe L, Kwon ED.

Cancer. 2007 Apr 15;109(8):1499-505.

8.

Costimulation, coinhibition and cancer.

Inman BA, Frigola X, Dong H, Kwon ED.

Curr Cancer Drug Targets. 2007 Feb;7(1):15-30. Review.

PMID:
17305475
9.

B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival.

Krambeck AE, Thompson RH, Dong H, Lohse CM, Park ES, Kuntz SM, Leibovich BC, Blute ML, Cheville JC, Kwon ED.

Proc Natl Acad Sci U S A. 2006 Jul 5;103(27):10391-6. Epub 2006 Jun 23.

10.

Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.

Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, Sengupta S, Frank I, Parker AS, Zincke H, Blute ML, Sebo TJ, Cheville JC, Kwon ED.

Cancer Res. 2006 Apr 1;66(7):3381-5.

11.

Genetically modified dendritic cells for cancer immunotherapy.

Ribas A.

Curr Gene Ther. 2005 Dec;5(6):619-28. Review.

PMID:
16457651
12.

The B7 family revisited.

Greenwald RJ, Freeman GJ, Sharpe AH.

Annu Rev Immunol. 2005;23:515-48. Review.

PMID:
15771580
13.

Novel role of prostate-specific membrane antigen in suppressing prostate cancer invasiveness.

Ghosh A, Wang X, Klein E, Heston WD.

Cancer Res. 2005 Feb 1;65(3):727-31.

14.

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED.

N Engl J Med. 2004 Oct 7;351(15):1513-20.

15.

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA; TAX 327 Investigators.

N Engl J Med. 2004 Oct 7;351(15):1502-12.

16.

The immune regulatory protein B7-H3 promotes osteoblast differentiation and bone mineralization.

Suh WK, Wang SX, Jheon AH, Moreno L, Yoshinaga SK, Ganss B, Sodek J, Grynpas MD, Mak TW.

Proc Natl Acad Sci U S A. 2004 Aug 31;101(35):12969-73. Epub 2004 Aug 18.

17.

Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis.

Castriconi R, Dondero A, Augugliaro R, Cantoni C, Carnemolla B, Sementa AR, Negri F, Conte R, Corrias MV, Moretta L, Moretta A, Bottino C.

Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12640-5. Epub 2004 Aug 16.

18.
19.

Murine B7-H3 is a negative regulator of T cells.

Prasad DV, Nguyen T, Li Z, Yang Y, Duong J, Wang Y, Dong C.

J Immunol. 2004 Aug 15;173(4):2500-6.

20.

Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer.

Ghosh A, Heston WD.

J Cell Biochem. 2004 Feb 15;91(3):528-39. Review.

PMID:
14755683

Supplemental Content

Support Center